PDMR Notification

Scancell Holdings Plc

06 December 2023

 

6 December 2023

Scancell Holdings plc

("Scancell" or the "Company")

PDMR Notification

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that further to the Company's announcement on the 1 December 2023 regarding the successful placing of ordinary shares of nominal value of 0.1 pence in the Company ("Shares") and the subscription for Shares by Dr Jean-Michel Cosséry and Professor Lindy Durrant, the following Shares were issued on 5 December 2023:

                   Dr Jean-Michel Cosséry                   454,545

                   Professor Lindy Durrant                   272,727          

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jean-Michel Cosséry
2	Reason for the notification
a)	Position/status	Chairman of Board and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Acquisition of ordinary shares
d)	Price(s) and volume(s)	454,545 ordinary shares at £0.11 per share
e)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
f)	Date of the transaction	5 December 2023
g)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Lindy Durant
2	Reason for the notification
a)	Position/status	Executive Director and PDMR
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Acquisition of ordinary shares
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Acquisition of ordinary shares
d)	Price(s) and volume(s)	272,727 ordinary shares at £0.11 per share
e)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
f)	Date of the transaction	5 December 2023
g)	Place of the transaction	Outside a trading venue

-ENDS-

For further information, please contact:
Scancell Holdings plc	[phone]
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

ICR Consilium	[phone]
Mary-Jane Elliott/Matthew Neal/Chris Welsh	[e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END